Autres langues Sonnet BioTherapeutics Holdings, Inc.

Actions

SONN

US83548R4020

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 23/06/2025			Varia. 5j.	Varia. 1 janv.
1,110 ^USD	-6,72%		-5,13%	-23,97%

13/05	Sonnet BioTherapeutics Holdings, Inc. publie ses résultats pour le deuxième trimestre et le semestre clos le 31 mars 2025	CI
04/04	Sonnet BioTherapeutics déclare que son médicament contre le cancer de l'ovaire a montré des données d'innocuité "positives" dans l'essai de phase 1b/2a ; les actions sont en hausse	MT

Autres langues

Sonnet BioTherapeutics Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2025	13/05
Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit	01/05
Sonnet Releases Virtual Investor "What This Means" Segment	16/04
Sonnet's SON-1010 demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose	07/04
Sonnet BioTherapeutics Says Ovarian Cancer Drug Showed 'Positive' Safety Data in Phase 1b/2a Trial; Shares Up	04/04
Sonnet Biotherapeutics Holdings, Inc. Announces Positive Safety Results of Son-1010 At the High Dose Combined with Atezolizumab in the Phase 1B/2A Clinical Trial in Adult Patients with Advanced Solid Tumors or Platinum-Resistant Ovarian Cancer	04/04
Sonnet'S Son-1010 Demonstrates A Strong Safety Profile In Combination With Atezolizumab For Treatment Of Platinum-Resistant Ovarian Cancer	04/04
Sonnet’s SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose	04/04
Sonnet Announces Release of Corporate Update Video	01/04
Sonnet Announces The Passing Of Founder And CEO Pankaj Mohan	01/04
Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D.	01/04
Sonnet BioTherapeutics Holdings, Inc. Announces CEO Changes	01/04
Sonnet BioTherapeutics Holdings, Inc. Announces Promotion of Stephen McAndrew from Chief Business Officer to President and Chief Business Officer	01/04
Sonnet BioTherapeutics Successfully Completes First Safety Review Of SON-1010 In Combination With Trabectedin In Certain Sarcomas	26/03
Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas	26/03
Sonnet BioTherapeutics Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas	26/03
Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein	19/03
Sonnet Bio Therapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of Its Il-18 Binding Protein Resistant Variant Protein	19/03
Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference	11/03
Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors	26/02
Sonnet Biotherapeutics Holdings, Inc. Presents Compilation of Data Highlighting the Potential of Son-1010 as A Monotherapy or A Combination Therapy to Improve the Treatment of Solid Tumors	26/02
Sonnet Biotherapeutics' Proprietary ADC Platform Available For Drug Discovery Partnerships	19/02
Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates	19/02
Sonnet Biotherapeutics Holdings, Inc. Announces Proprietary Antibody Drug Conjugate Platform Is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates	19/02
Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference	18/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Sonnet BioTherapeutics Holdings, Inc.

Actions

SONN

US83548R4020

Recherche biotechnologique et médicale

Autres langues

Filtres